Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.
Company profile
Website
CEO
Steven M. Klosk
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
222476135
Latest filings (excl ownership)
15-12B
Securities registration termination
16 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Dec 19
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|